Allogene Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2019 to Q2 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Allogene Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2019 to Q2 2025.
  • Allogene Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2025 was 31 %, a 23.2% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2025 31 +5.84 +23.2% Jun 30, 2025
Q1 2025 28.3 +3.53 +14.2% Mar 31, 2025
Q4 2024 27.3 +2.47 +9.94% Dec 31, 2024
Q3 2024 26.3 +2 +8.24% Sep 30, 2024
Q2 2024 25.1 +1.68 +7.16% Jun 30, 2024
Q1 2024 24.8 +2.99 +13.7% Mar 31, 2024
Q4 2023 24.9 +6.43 +34.9% Dec 31, 2023
Q3 2023 24.3 +8.14 +50.5% Sep 30, 2023
Q2 2023 23.5 +9.53 +68.4% Jun 30, 2023
Q1 2023 21.8 +9.92 +83.3% Mar 31, 2023
Q4 2022 18.4 +7.21 +64.3% Dec 31, 2022
Q3 2022 16.1 +4.61 +40% Sep 30, 2022
Q2 2022 13.9 +2.95 +26.9% Jun 30, 2022
Q1 2022 11.9 +1.45 +13.9% Mar 31, 2022
Q4 2021 11.2 +0.21 +1.91% Dec 31, 2021
Q3 2021 11.5 +1.01 +9.61% Sep 30, 2021
Q2 2021 11 -0.34 -3% Jun 30, 2021
Q1 2021 10.5 -2.49 -19.2% Mar 31, 2021
Q4 2020 11 -1.04 -8.64% Dec 31, 2020
Q3 2020 10.5 -0.51 -4.63% Sep 30, 2020
Q2 2020 11.3 -10.6 -48.3% Jun 30, 2020
Q1 2020 12.9 Mar 31, 2020
Q4 2019 12 Dec 31, 2019
Q3 2019 11 Sep 30, 2019
Q2 2019 21.9 Jun 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.